Treatment Outcomes and Toxicities of ABVD Combination Chemotherapy Compared with CVPP in Hodgkin's Disease.
10.5045/kjh.2007.42.4.335
- Author:
Yoon Seok CHOI
1
;
Byung Soo KIM
;
Hee Yeon SEO
;
Hwa Jung SUNG
;
Kyung Hwa PARK
;
In Keun CHOI
;
Seok Jin KIM
;
Sang Cheul OH
;
Jae Hong SEO
;
Chul Won CHOI
;
Sang Won SHIN
;
Yeul Hong KIM
;
Jun Suk KIM
Author Information
1. Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea. kbs0309@korea.ac.kr
- Publication Type:Original Article
- Keywords:
Hodgkin's disease;
Chemotherapy;
Toxicity
- MeSH:
Academic Medical Centers;
Bleomycin;
Disease-Free Survival;
Drug Therapy;
Drug Therapy, Combination*;
Hodgkin Disease*;
Humans;
Korea;
Medical Records;
Neutropenia;
Procarbazine;
Retrospective Studies;
Vinblastine
- From:Korean Journal of Hematology
2007;42(4):335-342
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: We retrospectively evaluated the treatment outcomes and toxicities of Hodgkin's disease (HD) patients treated by ABVD (adriamycin, bleomycin, vinblastine, and dacarbazine) combination chemotherapy, and compared them with those of a historical group treated with a CVPP (cyclophosphamide, vinblastine, procarbazine, and prednisone) regimen. METHODS: The medical records of patients who had been diagnosed with HD histologically and treated by either ABVD or CVPP from 1997 to 2006 at the Korea University Medical Center were retrospectively reviewed. RESULTS: Thirty patients were eligible. Nineteen patients received ABVD and eleven patients were treated with CVPP. The response rates for ABVD and CVPP were 84.21% and 54.55%, respectively. Median overall survival was 43.17 months for ABVD and 43.27 months for CVPP (P=.570). Median event-free survival was 39.03 months for ABVD and 16.73 months for CVPP (P=.088). There was no significant difference in median survival or in event-free survival between the two regimens. Hematologic toxicities were significantly more common in the CVPP group than in the ABVD group. Grade 3 or 4 neutropenia was observed in 72.72% of the CVPP group and in 36.84% of the ABVD group (P=.050). CONCLUSION: ABVD for HD showed significantly lower hematologic toxicities and moderately better treatment outcomes than did CVPP.
